KD Pharma expands CBD manufacturing capability with acquisition Fish oils supplier KD Pharma has moved more aggressively into the cannabinoid space with the acquisition of the manufacturing assets of a Swiss CBD and phyotextract specialist firm, the company announced today.
The new development will be tightly focused on supply active pharmaceutical ingredients for new drug development, said Adam Ismail, chief strategy officer for the company. To some degree it’s a statement about how the uncertain regulatory framework for hemp/CBD nutritional products in the United States, Europe and elsewhere is inhibiting innovation.
“Our focus is really on the pharma market for cannabinoids. That’s where we really see a lot of growth potential. It has a completely different regulatory framework from supplements,” Ismail told NutraIngredients-USA.
NPA’s Fabricant on CBD, NDI-related import alerts, and banned stimulants Efforts to move the needle on hemp-CBD at the Federal level are slow, and upcoming exits of key personnel at FDA are unlikely to affect progress much, says NPA’s Dr Daniel Fabricant. “In some ways I think FDA likes the status quo,” he tells NutraIngredients-USA.
The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act was re-introduced in the US House of Representatives in February with the aim of making hemp and hemp-derived CBD a dietary ingredient in dietary supplements.
Designated as HR 841, the bill directs the FDA to use its authority and resources to set a clear regulatory framework for hemp and hemp derived CBD and assure consumer protection. It has received widespread support from dietary supplement trade associations and hemp stakeholders, with NPA being the most notable dissenter for the bill because it fails to set a safe level of daily
NPA, others support CA CBD bill while still advocating for federal solution Yesterday the Natural Products Association testified in favor of a California bill to regulate the CBD trade in that state. NPA and others, however, have reiterated a call for federal legislation that would forestall the growing patchwork quilt of state regulations.
The bill, designated as SB-235, was introduced in the California Senate on Jan. 19 by Sen. Ben Allen. The bill is the counterpart of an Assembly bill (AB 45) that was introduced by Assemblywoman Cecilia Aguiar-Curry.
In absence of federal rules regarding the hemp/CBD trade, the bill would:
Industry group clarifies hemp definition in wake of Delta-8 THC confusion Recent news reports about the marketing of products featuring Delta-8 THC as a prominent constituent have muddied the waters enough that the US Hemp Roundtable felt it necessary to clarify again what should and shouldn’t be called a hemp product.
Recent headlines in both
The New York Times and
Rolling Stone magazine have created some confusion, said Jonathan Miller, an attorney in the firm Frost Brown Todd who is also general counsel for the roundtable, a hemp industry group.
Recent news reports obfuscate the issue
The Times headline read;
Misguided CBD brands in last minute novel foods panic, ACI warns Many UK CBD brands have been misled on how to prepare for the looming novel foods deadline meaning there is less than one month for some to pull together potentially impossible amounts of data, an industry expert has warned.
The Food Standards Agency UK (FSA) has given CBD companies a deadline of 31
st March 2021 to have a validated Novel Food License application submitted and many finished product brands may think they have done all they need to do.
But Shomi Malik, external affairs director at the ACI (Association for the Cannabinoid Industry), says there are some common misconceptions around what must be done to gain validation.